Regulation of adipocyte lipolysis

Gema Frühbeck1,2,3, Leire Méndez-Giménez1,2, José-Antonio Fernández-Formoso2, Secundino Fernández2,4 and Amaia Rodríguez1,2

1Metabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain
2CIBER Fisiopatología de la Obesidad y Nutrición (CIBERObn), ISCIII, Spain
3Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, Pamplona, Spain
4Department of Otorhinolaryngology, Clínica Universidad de Navarra, Pamplona, Spain

Abstract
In adipocytes the hydrolysis of TAG to produce fatty acids and glycerol under fasting conditions or times of elevated energy demands is tightly regulated by neuroendocrine signals, resulting in the activation of lipolytic enzymes. Among the classic regulators of lipolysis, adrenergic stimulation and the insulin-mediated control of lipid mobilisation are the best known. Initially, hormone-sensitive lipase (HSL) was thought to be the rate-limiting enzyme of the first lipolytic step, while we now know that adipocyte TAG lipase is the key enzyme for lipolysis initiation. Pivotal, previously unsuspected components have also been identified at the protective interface of the lipid droplet surface and in the signalling pathways that control lipolysis. Perilipin, comparative gene identification-58 (CGI-58) and other proteins of the lipid droplet surface are currently known to be key regulators of the lipolytic machinery, protecting or exposing the TAG core of the droplet to lipases. The neuroendocrine control of lipolysis is prototypically exerted by catecholaminergic stimulation and insulin-induced suppression, both of which affect cyclic AMP levels and hence the protein kinase A-mediated phosphorylation of HSL and perilipin. Interestingly, in recent decades adipose tissue has been shown to secrete a large number of adipokines, which exert direct effects on lipolysis, while adipocytes reportedly express a wide range of receptors for signals involved in lipid mobilisation. Recently recognised mediators of lipolysis include some adipokines, structural membrane proteins, atrial natriuretic peptides, AMP-activated protein kinase and mitogen-activated protein kinase. Lipolysis needs to be reanalysed from the broader perspective of its specific physiological or pathological context since basal or stimulated lipolytic rates occur under diverse conditions and by different mechanisms.

Key words: Catecholamines: Insulin: Hormone-sensitive lipase: Adipocyte TAG lipase: Perilipin: Adipokines: Lipid mobilisation

Introduction
Under normal conditions, the adipose tissue is able to fine-tune a series of neuroendocrine signals to precisely adapt the balance between TAG synthesis (lipogenesis) and breakdown (lipolysis) to meet physiological needs. In higher eukaryotes adipocyte TAG depots represent the major energy reserve of the organism as a result of the constant flux between lipolysis and re-esterification1–5. During energy surplus adipocytes accommodate the excess fuel as TAG for retrieval during periods of negative energy balance such as fasting, starvation or long-term exercise. The hydrolysis of TAG produces NEFA and glycerol that are released into the vasculature for use as energy substrates by other organs. Since TAG are not able to pass through biological membranes they need to be cleaved by TAG hydrolases, also termed lipases, before entering or exiting cells6,7. The ability to rapidly mobilise lipid reserves as NEFA to subvene energy demands represents a highly adapted metabolic response. In addition, the balance between the lipogenic drive and the lipolytic rate prevents an exaggerated elevation of plasma NEFA, which is considered a key aetiological factor in the development of insulin resistance8,9. Thus, the fat-storing ability of adipocytes prevents the appearance of lipotoxicity (lipid-induced dysfunction) and lipoapoptosis (lipid-induced programmed cell death) in other

Abbreviations: ACSL1, long-chain acyl-CoA synthetase 1; AMPK, AMP-activated protein kinase; AQP, aquaporin; ATGL, adipocyte TAG lipase; cAMP, cyclic AMP; CB, cannabinoid receptor; CD36, fatty acid translocase; CGI-58, comparative gene identification-58; Cide, cell death-inducing DFFA (DNA fragmentation factor-α)-like effector; COPI, coat protein complex I; DAG, diacylglycerol; ERK, extracellular signal-related kinase; FABP4, fatty acid-binding protein 4; FATP, fatty acid transport protein; G0S2, G0/G1 switch gene 2; GH, growth hormone; G i, G-inhibitory protein; GLP-1, glucagon-like peptide-1; HSL, hormone-sensitive lipase; IRS, insulin receptor substrate; LC3, light chain 3; LPL, lipoprotein lipase; MAP, mitogen-activated protein; MGL, monoacylglycerol lipase; mTOR, mammalian target of rapamycin; PDE-3B, phosphodiesterase-3B; P3K, phosphatidylinositol 3-kinase; PKA, protein kinase A; PTH, parathyroid hormone; RNAi, RNA interference; ZAG, Zn-α2-glycoprotein.

* Corresponding author: Dr Gema Frühbeck, fax +34 949 29 65 00, email gfruhbeck@unav.es
tissues (especially skeletal muscle and liver)\(^{(10–12)}\). While the metabolic importance of lipolysis remains unchanged, established models of adipose tissue lipolysis have undergone substantial revision lately. Notably, adipocyte lipid droplets are now considered dynamic organelles critical for the handling of lipid stores, containing specific structural proteins and lipid-metabolising enzymes involved in the modulation of both basal and hormone-regulated lipolysis\(^{(15–17)}\). Current knowledge in this field is reviewed from the broader perspective of providing an overview of the classic lipolytic factors as well as by focusing on the recently identified influence of the subcellular compartmentalisation of lipases, the relevance of lipid droplet proteins and lipid-binding proteins, as well as the activation of the different signalling pathways together with their regulation.

**Control of lipolysis**

Lipolysis constitutes the catabolic process leading to the breakdown of TAG into glycerol and NEFA in the adipose tissue\(^{(2)}\). Basal lipolytic activity of adipocytes is conditioned by sex, age, physical activity, fat depot location, species and genetic variance, whereas stimulated adipocyte lipolysis is regulated by multiple factors, which are depicted in Fig. 1 \(^{(18,19)}\). Interestingly, fat cell lipolysis exhibits species-unique characteristics based on the predominance of specific receptors and their relative density and expression \(^{(20,21)}\). A decreased lipolytic rate is observed both in the early years of life and the elderly in relation to the action of catecholamines and insulin \(^{(22–25)}\). For the same BMI, women exhibit higher NEFA circulating concentrations than men due to their constitutively larger fat depots and subcutaneous adipocytes \(^{(26)}\). Regional differences in the sensitivity to catecholamine-stimulated and insulin-inhibited lipolysis further underlie these sex-specific characteristics, which will be described more extensively below. An increased basal lipolysis together with an enhanced lipolytic sensitivity to catecholamines take place during situations of negative energy balance such as fasting, starvation or semi-starvation, contributing to the increased mobilisation of NEFA from adipocytes and the subsequent fat mass loss when maintained over time \(^{(2)}\). As in situations of energy deprivation, during prolonged exercise plasma NEFA increase in response to the elevated release of catecholamines and decreased production of insulin \(^{(27)}\). Both short- and long-term endurance training make adipocytes more sensitive to catecholamine stimulation via adrenoceptor signal transduction changes \(^{(28–31)}\).

Some dietary compounds also have the capacity to exert a direct impact on lipolysis regulation. The well-known lipolytic effect of caffeine and other methylxanthines occurs by elevating the cyclic AMP (cAMP) intracellular levels by two mechanisms. On the one hand, this is through \(A_1\)-adenosine receptor antagonism, leading to a reduction of adenylyl cyclase activity and subsequent increased lipolysis. On the other hand, methylxanthines further prevent the breakdown of cAMP by inhibiting phosphodiesterase \(^{(3)}\). Thus, coffee consumption increases lipid turnover and raises plasma NEFA, while a high intake of methylxanthines may also contribute to weight loss and maintenance through an enhanced fat oxidation and thermogenesis\(^{(32,33)}\). Another dietary compound influencing adipocyte lipolysis is Ca\(^{2+}\), with high intakes being associated with decreased adiposity and a reduced risk of obesity in diverse epidemiological studies\(^{(3)}\). Ca supplementation reportedly favours weight loss in both obese mice and human subjects undergoing energy-restricted diets, stimulating lipolysis via inhibition of the secretion of parathyroid hormone (PTH)\(^{(34)}\) and the subsequent activation of 25-hydroxycholecalciferol to 1,25-dihydroxycholecalciferol\(^{(35–38)}\). While acute ethanol intake exerts an anti-lipolytic effect, chronic ethanol consumption suppresses the \(\beta\)-adrenergic receptor-mediated lipolytic action via an increased activation of phosphodiesterase, resulting in a decreased protein kinase A (PKA) stimulation and a diminished activating phosphorylation of perilipin-1 and hormone-sensitive lipase (HSL)\(^{(39)}\).

Genetic variance also plays a role in determining lipolytic rate\(^{(5,18,40)}\). Variations in adrenoceptors have been intensely analysed for their putative functional effects on lipolysis and association with the development of obesity. The most studied are the polymorphisms in codon 64 of the \(\beta_3\)-adrenergic receptor and in codons 16, 27 and 164 of the \(\beta_2\)-adrenoceptor. The Trp64Arg missense mutation of the \(\beta_3\)-adrenergic receptor gene was reportedly associated with decreased lipolysis induced by \(\beta_3\)-adrenoceptor agonists\(^{(41)}\). However, other studies have failed to show any phenotypic effect of this polymorphism, so its true pathophysiological contribution to fat metabolism and energy homeostasis in humans remains controversial\(^{(38)}\). Noteworthy, variations in non-coding regions of calpain 10 lead to a decreased \(\beta_3\)-adrenergic receptor

---

**Fig. 1.** Main factors influencing adipocyte lipolysis. SNS, sympathetic nervous system; WAT, white adipose tissue. (A colour version of this figure can be found online at http://www.journals.cambridge.org/nrr)
function. In the β₂-adrenergic receptor gene the Arg16Gly mutation has been shown to be associated with altered β₂-adrenergic receptor function, with carriers of this mutation showing a five-fold increased agonist sensitivity(340). The Gln27Glu substitution was found to be twice as common in obese than in non-obese subjects in some populations, with homozygotes exhibiting an average excess fat mass of 20 kg and about 50 % larger fat cells(42). On the contrary, the rare Thr164Ile substitution in the β₂-adrenergic receptor gene has not been consistently observed in obese individuals. Polymorphisms in the G-β₃ gene, encoding for a specific G-coupling protein that links α₃ as well as β-adrenergic receptors to adenylate cyclase, alter catecholamine-induced lipolysis in human fat cells, improving the lipolytic function of β-adrenergceptors at the same time as enhancing the anti-lipolytic activity of α₂-adrenergceptors. Furthermore, variations in intrinsic dinucleotide repeats of the HSL gene are accompanied by a decreased function of the lipase with a reduced lipolytic effect of catecholamines(43,44).

**Classic factors**

In humans the main elements controlling lipolysis are the activity of the autonomic nervous system and the endocrine influence derived from the release of insulin(2,18,45). Adipose tissue is richly innervated by both the sympathetic and parasympathetic nervous systems with nerve terminals running along blood vessels and a certain number of adipocytes in direct contact with nerve varicosities. Thus, electrical stimulation of sympathetic nervous system nerve endings results in an increase in lipolytic activity, while surgical sympathectomy reportedly reduces lipolysis in the denervated adipose depot(46–49). Although the parasympathetic nervous system has been shown to also innervate white adipose tissue and decrease lipolysis, stimulating an increase in insulin sensitivity(50,51), its true functional role has been subsequently questioned(52).

**Catecholamine-induced regulation.** Catecholamines, adrenaline and noradrenaline, exert their impact on lipolysis upon binding to the diverse adrenergic receptor subtypes located on the plasma membrane of adipocytes(2,45,53). These receptors are linked to G-proteins, with G-protein receptor complexes regulating adenylate cyclase in the cell membrane. In mammals at least four adrenergceptors exert their action with marked species characteristics(41). In humans β₁- and β₂-adrenergceptors are the most active lipolytic elements, while the contribution of β₁-adrenergceptors remains to be better established. The presence of β₂-adrenergceptors in human white adipocytes has been clearly proven with tissue and subcellular distribution as well as response to stimulators being consistent with participation in lipolysis(540). However, the failure of β₂-adrenergceptor agonists to elicit clear-cut lipolytic and weight-loss effects in obese patients casted doubts on the true physiological relevance of this β-adrenergceptor subtype in humans(55,567). Contrarily, β₁-adrenergceptors are abundantly expressed in adipocytes of rodents(57). Upon binding to their ligand, β-adrenergceptors initiate the activation of the lipolytic cascade through the stimulation of cAMP production and subsequent activation of the cAMP-dependent PKA, which is followed by the phosphorylation of perilipin and HSL, ultimately leading to lipolysis stimulation (Fig. 2). Another peculiarity of human adipocytes resides in the presence of abundant α₂-adrenergceptors, which are coupled to G-inhibitory proteins (GI), thereby inhibiting cAMP production and, thus, lipolysis(58,59). Therefore, the balance between the lipolytic effect of β-adrenergceptors and the opposing anti-lipolytic activity of α₂-adrenergceptors also determines the net outcome of catecholamine-induced fat mobilisation in humans. The identification of brown adipose tissue in human adults beyond the vestigial amounts originally acknowledged and its association with BMI and adiposity has triggered a re-focusing of attention to the true relevance of β₂-adrenergceptors in lipid metabolism and energy homeostasis(60,61).

**Hormone-mediated control.** A number of hormones are known to participate in the regulation of lipolysis. Among all endocrine factors, insulin is quantitatively and qualitatively the most relevant one. The impact of growth hormone (GH), adrenocorticotropic hormone, cortisol, thyroid hormones, PTH and glucagon is comparatively much more reduced than that of insulin. The mechanisms of action of all are briefly discussed below.

**Hormone-mediated control: insulin.** Insulin is a key regulator of white adipose tissue biology, controlling not only lipogenesis but also the rate of lipolysis and NEFA efflux. Insulin regulates glucose uptake by adipocytes and triggers fatty acid transport protein translocation as well as fatty acid uptake by fat cells(62). Binding of insulin to its specific cell-surface receptor produces tyrosine phosphorylation and activation of the insulin receptor, which leads to the interaction with the insulin receptor substrates (IRS-1 and IRS-2), in turn activating the phosphatidylinositol 3-kinase (PI3K) complex(23). Insulin powerfully inhibits basal and catecholamine-induced lipolysis through phosphorylation (via a PKB/Akt-dependent action) and activation of phosphodiesterase-3B (PDE-3B). The phosphodiesterase catalyses the breakdown of cAMP to its inactive form, thereby decreasing cAMP levels, which in turn reduces PKA activation and, therefore, also translates into preventing HSL stimulation. Insulin may also suppress lipolysis through phosphorylation of the regulatory subunit of protein phosphatase-1 (PP-1), which once activated rapidly dephosphorylates and deactivates HSL, thus decreasing the lipolytic rate(63). The anti-lipolytic effect of insulin is observed already minutes upon binding of the hormone to its receptors.

**Hormone-mediated control: growth hormone.** While insulin represents the primary anabolic hormone exerting the main influence periprandially, GH operates directly and through stimulation of insulin growth factor-1, insulin
and NEFA during stress and fasting\textsuperscript{(64)}. Thus, GH represents a less potent though critically important regulator of lipolysis, which influences body composition, stimulating muscle mass accretion at the same time as reducing adiposity by a direct lipolytic effect using cAMP- and PKA-dependent pathways. GH-deficient individuals can experience up to a 40 % reduction in plasma NEFA and lipolysis that are returned to normal values by GH replacement therapy. Interestingly, GH activates adenylyl cyclase by selectively shifting the Gi\textsubscript{2} subunit and removing cAMP production inhibition\textsuperscript{(65)}. Exogenous GH administration produces an increase in NEFA after 2–3 h, thus reflecting a delayed lipolytic effect when compared with that of catecholamines. In this context, small physiological GH pulses reportedly increase interstitial glycerol levels in abdominal and femoral fat\textsuperscript{(66)}. In addition, suppression of the normal nocturnal rise in GH is followed by a reduction in subsequent lipolysis in subcutaneous adipose tissue\textsuperscript{(67)}. Endogenous GH has been shown to play a limited metabolic role during the daily fed–fast cycle, whereas it is essential for the increased lipolytic rate observed with more prolonged fasting\textsuperscript{(68)}. Recently, adipocyte-specific disruption of JAK2 (JAK2A) in mice has been shown to result in GH resistance in adipocytes, with reduced lipolysis and increased body fat, thereby offering complementary mechanistic insights into the well-recognised effects of GH on lipid flux\textsuperscript{(69)}.

\textbf{Hormone-mediated control: other hormones.} Cortisol also exerts a lipolytic effect, which is less potent than that of catecholamines at the same time as being delayed (minutes in the case of adrenaline v. hours for cortisol)\textsuperscript{(62,70)}. Importantly, the \textit{in vivo} lipolysis stimulation is counteracted by the corticoid-induced insulin release\textsuperscript{(71,72)}, whereby the net outcome of a short-term treatment with a standard dose of corticosteroids is an increase in abdominal adipose tissue lipolysis, without changes in GH concentrations, hyperglucagonaemia and insulin resistance. While a stimulation of lipolysis in human adipose tissue has been also ascribed to PTH\textsuperscript{(20,73)}, it has also been suggested that a PTH excess...
Adipocyte lipolysis control

may promote weight gain by impeding catecholamine-induced lipolysis\(^{(34)}\). Whereas in rodents testosterone up-regulates catecholamine-induced lipolysis\(^{(74)}\), in humans testosterone in physiological concentrations causes a depot-specific reduction of catecholamine-stimulated lipolysis in subcutaneous fat cells, probably due to reduced protein expression of β\(_2\)-adrenoceptors and HSL\(^{(75–77)}\). The relevance of androgen signalling in lipolysis regulation became evident from the observation that late-onset obesity development in androgen receptor-null male mice was caused in part by a decreased lipolytic activity\(^{(78)}\). The direct molecular mechanism accounting for the hypertrophic adipocytes and expanded white adipose tissue of these mice depends on an altered lipid homeostasis characterised by a decreased lipolysis but not an increased lipogenesis. Interestingly, transcripts for HSL were strikingly decreased, whereas those for lipogenic genes were unchanged or decreased. Androgens slightly decrease lipoprotein lipase (LPL) activity in human adipose tissue organ cultures, but markedly inhibit adipogenesis in primary preadipocyte cultures obtained from subcutaneous and omental depots of both sexes\(^{(79)}\). Thus, the androgenic effects on adipose tissue in men as opposed to women may differ more in terms of the magnitude of their negative impact on adipogenesis and lipid synthesis rather than in the direction of the lipolytic action.

Although commonly acting in rodent fat cells as lipolytic agents via stimulatory GTP-binding protein (G\(_\text{S}\) protein)-coupled receptors, thyrotropin-stimulating hormone, adrenocorticotropic hormone and α-melanocyte-stimulating hormone are either ineffective or very weak stimulators of lipolysis in human adipocytes\(^{(62)}\). Neither glucagon nor glucagon-like peptide-1 (GLP-1) has been clearly shown to stimulate lipolysis in vitro. Likewise, no significant effects of glucagon or GLP-1 on lipolytic rate or adipose tissue blood flow following local or experimental intravenous normo-and hyperglucagonaemia have been observed\(^{(80,81)}\). However, during the present decade the role of the GLP-1/GLP-1 receptor system in lipolysis has experienced renewed interest\(^{(82)}\). A dose-dependent lipolytic effect of GLP-1 in 3T3-L1 adipocytes in a receptor-dependent manner involving downstream adenylate cyclase/cAMP signalling has been shown\(^{(83)}\).

**Cytokines and other ‘newcomers’**

Over the past years adipose tissue has been recognised as an extraordinarily active endocrine organ with the ability to secrete numerous products of diverse nature such as hormones, cytokines, enzymes, complement factors, vaso-active peptides and growth factors, among others\(^{(84–87)}\). All these adipose-derived factors, collectively termed adipokines, are involved in a pleiad of physiological functions ranging from energy homeostasis to reproduction, including inflammation and immunity as well as angiogenesis and bone metabolism, among others\(^{(88–94)}\). The dynamic cross-talk of adipokines with other non-metabolic biological processes extends to the cardiovascular\(^{(95–99)}\), gastrointestinal\(^{(100–103)}\), respiratory\(^{(104–106)}\) and muscular\(^{(107–110)}\) systems. In addition to their participation in plentiful diverse physiological functions, many of the recently identified hormones and adipokines have also been shown to be able to directly affect lipolysis.

**Cytokine regulation of lipolysis.** Cytokine release by both adipocytes and stromovascular cells underlies the participation of adipose tissue in a dynamic cross-talk and potent feedback signalling with key neuroendocrine organs involved in the regulation of food intake, lipid metabolism, glucose disposal, energy expenditure and the stress response\(^{(111,112)}\). The complex secretory activities of adipose tissue also contribute to the development of insulin resistance and atherogenic processes\(^{(113–115)}\). The release of cytokines further exerts important local autocrine and paracrine effects, mainly involved in adipose tissue remodelling, adipogenesis, angiogenesis, inflammation and immunity. Noteworthy, cytokines, like TNF-α, as well as some interleukins and adipokines, are important regulators of spontaneous lipolysis.

**Cytokine regulation of lipolysis: TNF-α.** TNF-α is produced in large amounts by adipocytes and other cell types within adipose tissue\(^{(64,116)}\). In humans, contrary to rodents, TNF-α is not released from adipose tissue into the circulation but rather acts predominantly as a local factor\(^{(117–119)}\). As with other lipolytic agents, important species differences have also been observed as regards TNF-α action. TNF-α is able to stimulate lipolysis by at least three separate mechanisms\(^{(117,120,121)}\). First, it inhibits insulin receptor signalling, thereby counteracting the anti-lipolytic effect of the hormone. In this respect, TNF-α operates via the inactivation of IRS-1. This can be brought about by the inhibition of tyrosine phosphorylation and by a reduction in the amount of IRS-1 in adipocytes. In fact, TNF-α counteracts tyrosine phosphorylation by promoting serine phosphorylation of IRS-1. The most important TNF-α effect on adipocyte IRS-1 is mediated through the p42/44 mitogen-activated protein (MAP) kinase (Fig. 2). Second, TNF-α is able to stimulate lipolysis by inhibiting the G\(_\text{i}\)-protein-coupled adenosine receptor signalling to counteract the anti-lipolytic effect of adenosine. TNF-α markedly decreases the protein content of all three G\(_\text{i}\) protein subtypes in rodent fat cells, without changing the amount of G\(_\text{S}\) protein or β subunit of the G-protein complex. This decrease in G\(_\text{i}\) protein mitigates the anti-lipolytic effect of adenosine. Interestingly, TNF-α decreases G\(_\text{i}\)-protein content through an induction of protein degradation by the proteasomal pathway\(^{(122)}\). However, the TNF-α–G\(_\text{i}\) interaction appears to be specific for rodents because it has not been observed in human fat cells. The third way by which TNF-α induces lipolysis is via direct stimulation of basal lipolysis through interactions with the lipid-binding protein perilipin. Only TNF-α receptor 1 and MAP kinases promote lipolytic effects in fat cells leading to phosphorylation and
decreased production of perilipin, the adipose lipid droplet coating protein that protects it from being hydrolysed by HSL\(^{117,123,124}\). Three MAP kinases, namely p44/42, Jun kinase (JNK) and p38, are activated by TNF-\(\alpha\) in fat cells but only the first two have been linked to lipolysis so far.

Mechanistically, TNF-\(\alpha\) can stimulate lipolysis in the absence of insulin, thus providing evidence that it does not simply antagonise the anti-lipolytic effects of insulin. Moreover, extracellular glucose is required for the TNF-\(\alpha\)-induced lipolytic effect, suggesting that a certain nutritional state or substrate availability is required\(^{119}\). The downstream signals of the TNF-\(\alpha\) receptor 1-dependent pathway involve the activation of extracellular signal-related kinases (ERK1/2), JNK, AMP-activated protein kinase (AMPK), inhibitor of \(\beta\) kinase (IKK) and PKA\(^{119,125,126}\). However, in fat cells the TNF-\(\alpha\)-induced activation of ERK1/2, JNK and IKK is rapid and transient, while TNF-\(\alpha\)-induced lipolysis takes more than 6 h, suggesting the existence of more distant events that are likely to be controlled by transcriptional regulation\(^{119,127}\).

**Cytokine regulation of lipolysis: IL-6 and IL-15.** The IL-6 receptor and glycoprotein 130, key elements of the cytokine pathway, are expressed in human adipocytes, pointing to a direct autocrine/paracrine action of IL-6 on fat cells\(^{62}\). Infusions of recombinant human IL-6 have been reported to increase plasma NEFA and glycerol concentrations, leading the authors to conclude that IL-6 represents a novel lipolytic factor that operates as a potent stimulator of lipolysis\(^{128,129}\). Interestingly, IL-6 infusions were accompanied by parallel increases in plasma cortisol and adrenaline levels, whereas the infusions were accompanied by parallel increases in plasma cortisol and adrenaline levels, whereas the infusions were accompanied by parallel increases in plasma cortisol and adrenaline levels, whereas the infusions were accompanied by parallel increases in plasma cortisol and adrenaline levels, whereas the infusions were accompanied by parallel increases in plasma cortisol and adrenaline levels, whereas the infusions were accompanied by parallel increases in plasma cortisol and adrenaline levels, whereas the infusions were accompanied by parallel increases in plasma cortisol and adrenaline levels, whereas the infusions were accompanied by parallel increases in plasma cortisol and adrenaline levels, whereas the infusions were accompanied by parallel increases in plasma cortisol and adrenaline levels. In this regard, it is difficult to establish whether the increased lipolysis depends on the direct action of IL-6 or rather reflects the effects of other lipolytic factors such as GH, cortisol and noradrenaline\(^{130}\). A more recent study has shown that higher circulating IL-6 concentrations are associated with an increased isoproterenol-stimulated lipolysis especially in omental adipocytes in women\(^{131}\). In any case, the reported effect on lipolysis of IL-6 is relatively modest compared with that elicited by catecholamines and insulin. The potential involvement of IL-6 during the practice of exercise or other situations related to severe illness, where a clear need for an elevated lipid fuel takes place, has been set forward\(^{132,133}\).

Another member of the interleukin family has been proposed to participate in the modulation of lipolysis. The administration of IL-15 has been shown to produce a significant reduction in white adipose tissue via both a decreased rate of lipogenesis and a reduction in LPL activity, without a concomitant decrease in food intake\(^{134}\). Comparative studies with other cytokines revealed that IL-15 is apparently more potent in its acute stimulation of lipolysis than IL-6 and TNF-\(\alpha\)\(^{135}\). Noteworthy, when specific inhibitors of PKA or Janus kinase were present an attenuation of the lipolytic effect of IL-15 was observed. IL-15 is known to be highly expressed in skeletal muscle, exerting a potent anabolic effect on muscle protein accretion while decreasing fat depots in adipose tissue\(^{136}\). Taking these observations together, it can be speculated that IL-15 may operate as a homeoregulatory factor that mobilises and directs energy away from the adipocyte to other cells during the acute phase of the inflammatory response.

Interestingly, IL-1B and TNF-\(\alpha\) have been shown to activate MAP3K8, also called Tpl2, which is expressed in adipocytes and is implicated in cytokine-induced lipolysis\(^{127}\). Pharmacological inhibition or silencing of Tpl2 was able to prevent MAP kinase kinas/ERK1/2 activation by these cytokines but not by insulin, thereby providing evidence of its involvement in ERK1/2 activation particularly in response to inflammatory stimuli\(^{127}\).

**Cytokine regulation of lipolysis: leptin.** More than a decade ago the identification of functional leptin receptors (OB-R) in white adipose tissue suggested the involvement of leptin in the direct peripheral regulation of adipocyte metabolism\(^{137–139}\). In fact, leptin was shown to directly participate in lipid metabolism control through the inhibition of lipogenesis and the stimulation of lipolysis. Leptin reportedly exerts an autocrine–paracrine lipolytic effect on isolated white adipocytes both in vitro and ex vivo\(^{140–145}\).

Adenosine A1 receptors have been shown to be markedly expressed in adipocytes and influence fat cell metabolism via the regulation of adenylyl cyclase and, therefore, participate in lipolysis control via the inhibitory guanosine 5′-triphosphate (GTP) binding proteins, Gi\(^{144,145}\). The adenosinergic system increases leptin secretion by directly activating adenosine A1 in white adipose tissue\(^{146}\). In this respect, a defective leptin-induced stimulation of lipolysis that opposes the adenosine-mediated tonic inhibition was identified\(^{145}\). Interestingly, the lipolytic effect of leptin is located at the adenylyl cyclase-inhibitory G protein step (Fig. 2), providing an explanation for the defective stimulation of adipocyte adenylylcyclase and the blunted lipolysis observed in leptin-deficient and OB-R-lacking rodents as well as in morbidly obese humans\(^{147–149}\). Moreover, storage of surplus energy in white adipose tissue and the development of diet-induced obesity require the blockade of a latent leptin-stimulated energy sump in white adipocytes\(^{150}\). In this regard, the pleiotropic effects of leptin in other metabolically relevant organs like brown adipose tissue, skeletal muscle, pancreas, liver and heart need to be considered\(^{150,151–157}\).

**Cytokine regulation of lipolysis: adiponectin.** Adiponectin, also known as Acrp30, AdipoQ, apM1 or GBP28, is a hydrophilic 30-kDa protein highly expressed and secreted by adipocytes\(^{158,159}\). The three-dimensional structure of the C-terminal globular domain of adiponectin shows a high structural homology with TNF-\(\alpha\), another well-known lipolytic cytokine\(^{150}\). Interestingly, HSL activity has been shown to be positively correlated to adiponectin expression, with percentage body fat and adiponectin...
mRNA arising as the only independent predictors of adipose tissue HSL activity explaining 26% of its variability (159). Increased adipose tissue mass has been suggested to explain the association between low adiponectin and reduced NEFA tolerance (160). Adiponectin has been shown to inhibit spontaneous and catecholamine-induced lipolysis in human adipocytes of non-obese subjects through AMPK-dependent mechanisms (161). In contrast to most adipokines, which are markedly up-regulated in obesity, adipose tissue expression and circulating concentrations of adiponectin are decreased in both overweight and obesity, thereby implying a plausibly decreased impact on overall lipolysis. Adiponectin gene knockout mice and primary adipocytes obtained from these mice exhibit an increased lipolysis (162). Moreover, adiponectin was shown to suppress HSL activation without modifying adipocyte TAG lipase (ATGL) and comparative gene identification-58 (CGI-58) expression in adipocytes. In addition, adiponectin reportedly reduced the type 2 regulatory subunit RII protein levels of PKA by reducing its protein stability, with ectopic expression of RIIa abolishing the inhibitory effects of adiponectin on lipolysis in adipocytes (162). The proportion of secreted high-molecular-weight v. total adiponectin has been shown to be higher in visceral than in subcutaneous adipose tissue explants in non-obese individuals, while no differences were observed in obese individuals (163). More recently, full-length adiponectin was shown to exert an anti-lipolytic effect in non-obese subcutaneous adipose tissue, while the globular and trimeric isoforms exhibited anti-lipolytic activity in obese subcutaneous and visceral adipose tissue, respectively (164).

**Other elements involved in lipolysis.** Analysis of the involvement of other factors in the control of lipolytic pathways is unravelling a huge number of potential modulators, which vary greatly not only in their biochemical structure but also in their main physiological effect and the signalling cascade activated.

**Other elements involved in lipolysis: nitric oxide.** NO or related redox species have been described as acting as regulators of lipolysis both in rodent and human adipocytes (165–170). Inhibition of NO release increased lipolysis independently of local blood flow changes. While chemical NO donors stimulate basal lipolysis, they block the characteristic isoproterenol-induced lipolytic activity via the inhibition of adenylyl cyclase and PKA. Inducible NO synthase has emerged as a negative modulator of lipolysis via an oxidative signalling pathway upstream of cAMP production (169). A functional relationship between leptin and NO has been established in several physiological processes (139, 171–175). Given the co-localisation of both factors in fat cells and their involvement in lipolysis, a potential role of NO in the leptin-induced lipolytic effect seemed plausible. In fact, 1 h after exogenous leptin administration a dose-dependent increase in both serum NO concentrations and basal adipose tissue lipolytic rate was observed (143). Up to 27% of the variability taking place in lipolysis was attributable to the changes in NO concentrations. The leptin-induced NO production in white adipocytes was shown to be mediated through PKA and MAP kinase activation (176). Inhibition of NO synthesis by Nω-nitro-arginine methyl ester (l-NAME) pretreatment was followed by a reduction in the leptin-mediated lipolysis stimulation compared with leptin-treated control animals. Contrastly, in adipocytes obtained from rats under acute ganglionic blockade, the leptin-induced lipolytic effect did not show differences with the lipolytic rate achieved by leptin in control rats. The NO donor S-nitroso-N-acetyl-penicillamine (SNAP) was able to exert a significant inhibitory effect on isoproterenol-stimulated lipolysis. Thus, NO has emerged as a potentially relevant autocrine–paracrine physiological signal to fine-tune lipolysis by facilitating leptin-induced lipolysis and, at the same time, being able to inhibit catecholamine-induced lipolysis (173).

**Other elements involved in lipolysis: natriuretic peptides.** Until recently, human fat cell lipolysis was thought to be mediated essentially by a cAMP-dependent PKA-regulated pathway under the control of catecholamines and insulin. However, Lafontan et al. (177) provided evidence that natriuretic peptides also have the ability to potentially stimulate lipolysis in human adipocytes to the same degree as a non-selective β-adrenoceptor agonist. This lipolytic effect is mediated mainly by natriuretic peptide receptor type A through a cyclic GMP-dependent PKG (cGK-I) signalling pathway (Fig. 2) that does not involve PDE-3B inhibition or cAMP production and PKA activity (178–182). Noteworthy, in vitro studies have shown that HSL can also be phosphorylated by the cyclic GMP-dependent signalling cascade. In fact, cGK-I phosphorlates perilipin and HSL. Increases in plasma atrial natriuretic peptide levels by physiological (exercise) or pharmacological stimuli are followed by an enhanced lipid mobilisation (185, 186). In humans atrial natriuretic peptide also reportedly induces postprandial lipid oxidation, energy expenditure, and concomitantly arterial blood pressure (185, 186). Taken together, this pathway that participates in lipid mobilisation and energy homeostasis becomes especially important during chronic treatment with β-adrenoceptor antagonists, which inhibit catecholamine-induced lipolysis but enhance cardiac atrial natriuretic peptide release.

**Other elements involved in lipolysis: endocannabinoid system.** Our understanding of the participation of the endocannabinoid system in energy homeostasis has progressed enormously over the past years (187–189). In particular, the observation of the presence of G protein-coupled cannabinoid receptor (CB) CB1 receptors in adipocytes provided a clue for the involvement of endocannabinoids in the peripheral control of lipid metabolism (190–193). Selective CB1 antagonism was shown to coordinate induce key genes of the fatty acid catabolic pathway, thereby favouring lipolysis and reducing fat storage in adipose tissue (191). Interestingly, the selective...
antagonism of CB1 receptors reportedly induced β3-adrenoceptors and GH receptors at the same time as the expression of catechol-O-methyltransferase, an enzyme involved in the degradation of catecholamines. The reduced expression of this methyltransferase along with the induction of the receptors of two well-known hormones with lipolytic effects further supports the molecular basis for the participation of endocannabinoids in the modulation of lipolysis.

Amides of fatty acids with ethanolamine (FAE) are biologically active lipids participating in a variety of physiological effects, including appetite regulation. While the polyunsaturated FAE anandamide (arachidonoylthanolamide) increases food intake by activating G protein-coupled cannabinoid receptors, the monounsaturated FAE oleoylthanolamid (OEA) reduces feeding as well as body-weight gain and stimulates lipolysis by activating the nuclear receptor PPAR-α(194,195).

Other elements involved in lipolysis: ghrelin. Beyond its strong orexigenic effect, the gastrointestinal twenty-eight-amino acid octanoylated peptide ghrelin exerts a wide spectrum of actions including the inhibition of isoproterenol-induced lipolysis in rodent adipocytes(196). Both ghrelin and des-acyl ghrelin have been shown to antagonise the catecholamine-stimulated lipolysis via a non-type 1A GH secretagogue receptor. Moreover, acylated and unacylated ghrelin have been also shown to attenuate isoproterenol-induced lipolysis in isolated rat visceral adipocytes through activation of phosphoinositide 3-kinase γ and PDE-3B(197).

However, ghrelin infusion in human subjects was observed to induce acute insulin resistance and lipolysis independent of GH signalling(198). All of the elements of the ghrelin system have been identified in human adipocytes, including receptors and isoforms as well as the ghrelin-3-acyltransferase or GOAT enzyme(199,200). Interestingly, in differentiating omental adipocytes, incubation with both acylated and desacyl ghrelin increased PPAR-γ and sterol regulatory element-binding protein-1 mRNA levels, as well as fat storage-related proteins, like acetyl-CoA carboxylase, fatty acid synthase, LPL, and perilipin(199). Consequently, both ghrelin forms stimulate intracytoplasmatic lipid accumulation at the same time as exhibiting an anti-lipolytic effect.

Other elements involved in lipolysis: other miscellaneous agents. The potent anti-lipolytic effect of nicotinic acid together with its specific binding to adipose tissue was firmly established more than half a century ago(201,202). However, the mechanistic basis for this action on lipolysis control has been provided only more recently(203). Activation of the nicotinic acid receptor triggers an inhibitory G-protein signal, which decreases cAMP concentrations in adipocytes, thereby inhibiting lipolysis. Continuous 24 h nicotinic acid infusion in rats reportedly alters gene expression and basal lipolysis in adipose tissue, producing a NEFA rebound and insulin resistance(204) that are consistent with clinical observations following treatment with this compound.

Other agents originating from either adipocytes or surrounding cells are known to negatively control adenylyl cyclase activity and inhibit lipolysis via their interaction with plasma membrane receptors belonging to the seven-transmembrane domain receptor family. Autacoid agents, as already mentioned including adenosine, prostaglandins and their metabolites, exert a clear anti-lipolytic effect. Whereas adenosine and neuuropeptide Y reportedly inhibit lipolysis, for PGE2 a biphasic effect has been put forward with nanomolar concentrations suppressing lipolysis, but micromolar levels resulting in lipolysis stimulation(65). On the contrary, PGI2 showed no effect or exerted also a biphasic effect, whereby nanomolar concentrations stimulated lipolysis, whereas at micromolar levels lipolysis was suppressed.

Cachexia-inducing tumours produce a lipid-mobilising factor (LMF) that causes an immediate glycerol release when incubated with murine adipocytes, with the stimulation of lipolysis by LMF being associated with an elevation in intracellular cAMP concentrations(205–207). Zn-α2-glycoprotein (ZAG), a tumour-related LMF of 43 kDa, has been found to be expressed in 3T3-L1 cells as well as in the major fat depots of mice, being up-regulated in rodents with cancer cachexia(208). Both ZAG expression and protein have been also detected in human adipocytes of visceral and subcutaneous origin. Remodelling of adipose tissue together with decreased lipid storage constitute a hallmark of cancer patients with cachexia. In addition to ATGL- and HSL-enhanced lipolysis, in cancer other factors such as ZAG have been shown to participate in TAG degradation leading to white adipose tissue atrophy. ZAG expression and release by adipose tissue are up-regulated in weight-losing cancer patients, suggesting that ZAG operates both locally and systemically to stimulate lipid mobilisation(206). However, ZAG did not display the thermogenic effects of the β-adrenergocceptor agonist, nor did it increase β3-adrenergocceptor or UCP1 (uncoupling protein 1) gene expression in brown adipose tissue, thereby implying that it does not behave as a typical β3-adrenergocceptor agonist(209). Thus, ZAG has emerged as a novel adipokine, being identified as an additional adipose tissue factor closely related to body weight loss not only via modulation of lipolysis in fat cells but also by activating AMPK in skeletal muscle cells(208,210).

The octapeptide angiotensin II (Ang II) is the active component of the renin–angiotensin system (RAS). A local RAS is present in adipose tissue, with all the elements of the system, including angiotensinogen, renin and angiotensin-converting enzyme, having been identified in adipocytes(211). Noteworthy, Ang II has been shown to decrease local blood flow in a dose-dependent manner and to inhibit lipolysis in adipose tissue with the effects being similar in both normal-weight and obese individuals(212). In the last decade evidence has been provided that adipose tissue is a source of vasoactive peptides that further exert metabolic actions(213). Thus, endothelin-1 is...
a powerful vasoconstrictor primarily produced and secreted by endothelial cells to operate on the underlying vascular smooth muscle cell layer that can also act on adipocytes inducing lipolysis via the ERK pathway (214,215). In human subjects endothelin-1 has been shown to selectively counteract insulin inhibition of visceral adipocyte lipolysis, decreasing the expression of insulin receptor, IRS-1 and PDE-3B and increasing the expression of the endothelin receptor-B (ET\textsubscript{B}R) in visceral but not subcutaneous adipocytes (216). The ET\textsubscript{B}R-mediated effects were signalled via the PKC and calmodulin pathways. Subsequently, it was further observed that long-term incubation of human adipocytes with endothelin-1 increases lipolysis via the activation of ET\textsubscript{B}R (217). Likewise, the fifty-two amino acid vasoactive peptide adrenomedullin together with its receptor components (calcitonin receptor-like receptor and receptor activity modifying protein-2 (CRLR/RAMP2)) have been identified to be concomitantly expressed in adipose tissue (Fig. 2), exhibiting a tissue-specific up-regulation during the development of obesity (218,219). Interestingly, in adipose tissue adrenomedullin acts as an autocrine–paracrine factor to regulate lipid mobilisation, inhibiting lipolysis through NO-mediated \(\beta\)-adrenergic agonist-oxidation (220). In this context, it has been proposed that adrenomedullin alone is devoid of lipolytic function and inhibits \(\beta\)-adrenergic-stimulated lipolysis by shifting the concentration–response curve for isoproterenol by a NO-dependent mechanism; specifically, adrenomedullin-induced NO modifies isoproterenol through an extracellular oxidative reaction to yield its aminochrome, isoprenochrome. However, other studies have provided evidence for adrenomedullin dose-dependently elevating cAMP levels and the lipolytic rate (221). In this case, adrenomedullin was shown to increase the phosphorylation of PKA, ERK and Akt and would reportedly exhibit additive effects on isoproterenol-induced lipolysis.

Apelin represents a further peptide with vasoactive characteristics that has been subsequently shown to be secreted by adipocytes of both humans and rodents, being up-regulated in states of obesity (222). The identification in adipocytes of apelin and the apelin receptor (AP), a G-protein-coupled receptor, supported a plausible autocrine participation of this peptide in adipobiology. In this line, apelin was shown to dose-dependently stimulate AMPK phosphorylation in human adipose tissue, which was associated with increased glucose uptake (223). Apelin reportedly decreased isoproterenol-induced NEFA and glycerol release in 3T3-L1 cells and isolated adipocytes abrogating the catecholamine-induced HSL phosphorylation via G-protein q polypeptide (G\textsubscript{q}), G\textsubscript{i} pathways and AMPK activation (224). The apelin-induced inhibition of basal lipolysis was exerted through AMPK-dependent enhancement of perilipin expression by preventing lipid droplet fragmentation and hormone-stimulated acute lipolysis inhibition mediated by decreasing perilipin phosphorylation (225). Moreover, apelin also suppressed adipogenesis through MAP kinase kinase/ERK signalling.

Pigment epithelium-derived factor (PEDF) is a 50-kDa protein of the non-inhibitory serpin family of serine protease inhibitors originally identified as a regulator of hepatic TAG metabolism involved in the development of insulin resistance in obesity (6,226,227). Subsequently it was tested whether this adipocyte-secreted factor also exhibits autocrine–paracrine lipolytic effects. PEDF was shown to stimulate TAG hydrolysis in adipose tissue, muscle and liver via ATGL (226). The exact mechanisms underlying the participation of PEDF in insulin resistance, obesity and non-alcoholic fatty liver disease still need to be fully elucidated (229–231). The potential role of other recently identified adipocyte-related factors on lipolysis such as serum amyloid A, osteopontin, osteocalcin, osteoprotegerin, obestatin, lipocalin 2, visfatin, nerve growth factor-inducible derived peptides, omentin, mammalian chitinase-like protein YKL40, chemerin, vitamin D and tenasin C, among others, beyond their originally reported effects merits to be specifically investigated (232,233,234).

**Influence of subcellular compartmentalisation of lipases**

Multicellular organisms ranging from insects to mammals have evolved specialised systems to store surplus lipid energy for subsequent mobilisation in times of need. In mammals the storage and mobilisation of lipids are fundamental functions of adipocytes. About 80% of the total adipose tissue weight is due to the fat content, with over 90% of lipids being stored as TAG (246). The major secretory products of adipose tissue are NEFA (247), which are derived from the lipolysis of stored TAG in a process involving three main steps and requiring, at least, three different lipases, which are regulated by both adipocyte and non-adipocyte factors (7). Thus, the classic lipolytic pathway encompasses the three following consecutive steps: (i) TAG hydrolysis by ATGL to generate fatty acids and diacylglycerol (DAG) (248); (ii) subsequently, HSL catalyses the hydrolysis of DAG to monoacylglycerol (MAG) and fatty acids (249,250); (iii) monoacylglycerol lipase (MGL) is required to complete the hydrolysis of MAG into one fatty acid and glycerol (251). HSL and ATGL are quantitatively the most important lipases based on the blunted isoprenaline-induced lipolysis observed in adipocytes of Atgl- and Hsl\textsuperscript{-}-knockout mice (249,252).

**TAG hydrolysis.** Only a decade ago the initiation of TAG hydrolysis was thought to be exclusively controlled by HSL (2–7,253–255). However, the generation of Hsl\textsuperscript{-}-knockout mice revealed the existence of residual HSL-independent TAG lipase activity, pointing to the existence of previously unidentified adipose tissue lipases. Currently, ATGL is well recognised to be the lipase responsible for initiating TAG breakdown to yield DAG (7,5,6). ATGL is a 54-kDa TAG hydrolase, also named phospholipase A2\textsubscript{f} or desnutrin, belonging to the family of patatin-like phospholipase domain-containing proteins (PNPLA) with specificity for TAG as a substrate (6,248,256,257). Atgl-knockout mice and
knockdown studies in adipocytes provided evidence for the involvement of ATGL in TAG but not DAG hydrolysis. Atgl-null mice exhibited a blunted lipolysis, producing a more than 75% reduction in NEFA release and a significant TAG accumulation in adipocytes leading to obesity. The co-activator of ATGL, CGI-58, also known as α/β-hydrolase domain-containing protein 5 (ABHD5), was shown to stimulate TAG hydrolysis activity in wild-type and Hsl-deficient but not Atgl-deficient mice. ATGL and HSL are responsible for 95% of TAG lipase activity, thereby suggesting a complementary relationship between the two lipases.

ATGL is highly expressed in adipose tissue, with its expression being profoundly elevated during adipocyte differentiation. Two phosphorylation sites (Ser404 and Ser428) have been identified within the C-terminal region of ATGL. Furthermore, the enzymic activity and its interaction with CGI-58 are dependent on the C-terminal region. Overexpression of Atgl elevates TAG hydrolysis as well as basal and catecholamine-stimulated lipolysis, while Atgl silencing decreases TAG hydrolyase activity, TAG storage and lipid droplet size. Alterations of Atgl expression resulted in dramatic changes in whole-cell lipolysis. Conversely, silencing of Atgl or CGI-58 significantly reduced basal lipolysis and essentially abolished forskolin-stimulated lipolysis. Taken together, these findings suggest that in humans the ATGL–CGI-58 complex acts independently of HSL and precedes its action in the sequential hydrolysis of TAG.

Fasting, glucocorticoids and PPAR agonists increase Atgl mRNA expression, whereas food intake and insulin decrease it. Cellular TAG lipolysis by ATGL produces essential mediators involved in lipid ligand generation for PPAR activation, with Atgl deficiency in mice reducing mRNA levels of PPAR-α and PPAR-δ target genes. While mammalian target of rapamycin (mTOR)-dependent signalling has been observed to decrease Atgl mRNA expression, FoxO1 activation by SIRT1-mediated deacetylation elevated it. However, the role of AMPK in lipolysis control remains controversial. In this sense, the precise mechanisms of ATGL regulation need to be fully established. Recently, a protein encoded by the G0/G1 switch gene 2 (G0S2) has been identified as a selective regulator of ATGL by attenuating its action both in vitro and in vivo. G0S2 is highly expressed in adipose tissue and differentiates adipocytes interacting specifically with ATGL to inhibit its TAG hydrolyase activity. While knockdown of endogenous G0S2 enhances both basal and stimulated lipolysis in adipocytes, overexpression of G0S2 decreases the lipolytic rate of adipocytes and adipose tissue explants. G0S2 has been further shown to regulate human lipolysis influencing ATGL activity and intracellular localisation by anchoring the lipase to lipid droplets (Fig. 3) independently of the C-terminal lipid-binding domain of ATGL. Moreover, G0S2 expression has been observed to be diminished in poorly controlled type 2 diabetes, thereby establishing a potential link between adipose tissue G0S2 down-regulation and insulin resistance. Given that the above-mentioned characteristics reveal ATGL as an attractive therapeutic target, the development and characterisation of a selective small-molecule inhibitor of ATGL, atglistatin, may prove of interest for the pharmacological treatment of dyslipidaemic and metabolic disorders.

**Diacylglycerol hydrolysis.** HSL, an 84-kDa cytoplasmic protein with demonstrated activity for a wide range of substrates including TAG, DAG, cholesteryl esters and retinyl esters, was presumed to be the rate-limiting enzyme in the initial steps of the lipolytic process. However, several important findings challenged this view of the unique regulatory and rate-limiting role of HSL on lipolysis, pointing to the existence of alternative lipases targeting TAG molecules to counterbalance the strong affinity of HSL for DAG: (i) PKA-dependent HSL phosphorylation led only to a 2- to 3-fold increase in TAG hydrolyse activity, while whole-cell lipolysis resulted in a 100-fold increase; (ii) Hsl-null mice exhibited a normal body weight with decreased adiposity; (iii) these mutants further showed DAG adipocyte accumulation; (iv) the existence of residual TAG hydrolyase activity and lipolysis despite HSL silencing or specific pharmacological inhibition; and (v) failure of HSL overexpression to promote whole-cell lipolysis. As mentioned previously, the identification of ATGL provided explanations for these findings.

Fig. 3 illustrates ATGL and HSL regulation in basal and stimulated conditions. ATGL and HSL have the capacity to hydrolyse in vitro the first ester bond of TAG. ATGL exhibits 10-fold higher substrate specificity for TAG than DAG, selectively enabling the first step in TAG hydrolysis, leading to the formation of DAG and fatty acid. An important step in lipolysis activation comprises the translocation of HSL from a cytosolic compartment to the surface of the lipid droplet. Upon lipolytic stimulation, HSL moves from the cytosol to the surface of lipid droplets where it interacts with perilipin-1 and neutral lipids. Noteworthy, adipocytes lacking perilipin-1 are incapable of translocating HSL to the lipid droplet after increases in cAMP. Perilipin-1 operates as a dynamic scaffold to coordinate the access of enzymes to the lipid droplet in a way that is responsive to the metabolic state of the adipocyte. Thus, in basal conditions (Fig. 3(a)) perilipin-1 limits lipase access to the lipid droplet. Lipolysis simulation is followed by HSL translocation from the cytosol to lipid droplets and redistribution of ATGL, resulting in enriched colocalisation of the two lipases. Interestingly, the ATGL–CGI-58 complex acts independently of HSL and precedes its action in the sequential hydrolysis of TAG in humans. The increased number of ATGL–CGI-58 complexes formed following perilipin-1 phosphorylation (which releases CGI-58) and docked on small lipid droplets govern PKA-stimulated lipolysis (Fig. 3(b)).
between fatty acid binding protein 4 (FABP4) and HSL represents a further regulatory step. Fatty acid binding to FABP4 and HSL phosphorylation precede the association of FABP4 and HSL. FABP4 also participates in the trafficking of fatty acids from the site of hydrolysis (i.e. the lipid droplet) to the plasma membrane. In addition to supporting fatty acid trafficking to the plasma membrane in a reaction that is independent of its physical association with HSL, FABP4 bound to fatty acids associates with activated, phosphorylated HSL on the surface of lipid droplets. The sequential effect of ATGL-accentuated TAG hydrolysis, phosphorylated HSL and MGL activity yields massive increases in NEFA release in response to PKA activation.

The expression profile of HSL basically mirrors that of ATGL, given that both enzymes coordinately hydrolyse TAG and, therefore, share some regulatory characteristics but differ in the mechanisms of enzyme control.\(^6\). Whereas

---

*Fig. 3.* Schematic representation of basal (a) and stimulated (b) lipolysis, the catabolic pathway by which TAG are hydrolysed into fatty acids (FA). AC, adenyl cyclase; ATGL, adipocyte TAG lipase; cAMP, cyclic AMP; CGI-58, comparative gene identification-58; DAG, diacylglycerol; FABP4, fatty acid binding protein 4; G0S2, G0/G1 switch gene 2; Gs, stimulatory GTP-binding proteins; HSL, hormone-sensitive lipase; MAG, monoacylglycerol; MGL, monoacylglycerol lipase; P, phosphate; PKA, protein kinase A. (A colour version of this figure can be found online at http://www.journals.cambridge.org/nrr)
β-adrenergic stimulation exerts ATGL regulation mainly via PKA-catalysed phosphorylation. Adipocyte HSL encompasses an N-terminal domain (that interacts with FABP4) and a C-terminal catalytic domain (that contains the active site as well as a regulatory module with all the known phosphorylation sites of HSL). Phosphorylation of HSL at Ser563, Ser569 and Ser660 by PKA and at Ser660 via the ERK pathway activates lipolysis. The PKA-dependent lipolytic effect is exerted increasing HSL’s intrinsic activity and promoting its access to TAG molecules within the adipocyte. Conversely, AMPK exerts an anti-lipolytic effect, blocking the translocation of HSL to the lipid droplets by its phosphorylation at Ser565. Deactivation of lipolysis mediated by insulin is associated with down-regulation of HSL and ATGL expression. Moreover, insulin signalling phosphorylates and activates PDE isoforms via PKB, CAMP hydrolysis and PKA inhibition, resulting in the prevention of HSL and perilipin-1 phosphorylation, HSL activation and translocation as well as CGI-58-mediated ATGL activation. The peripheral control of insulin is accompanied by a central mechanism via the sympathetic nervous system that reduces the activity of both HSL and ATGL.

Monoacylglycerol hydrolysis. The final step of lipolysis is catalysed by MGL, which is constitutively expressed in adipose tissue and has no affinity for DAG, TAG or choles-teryl esters. The enzymatic activity of MGL is required in the final hydrolysis of the 2-monoacylglycerols produced by HSL activation. Site-directed mutagenesis has shown the relevance of Ser122, Asp239 and His269 in the lipolytic activity and functions in stabilising lipid droplets.

Other lipases. The contribution of alternative lipases to ATGL and HSL to the overall lipolytic capacity and maintenance of the highly dynamic TAG turnover has yet to be completely discerned. Potential TAG hydrolases have been identified within members of the carboxylesterase/ lipase and the patatin homology domain families. Carboxylesterase-3/TAG hydrolase-1 is supposedly involved in HSL-independent lipolysis in adipocytes and participates in the assembly and secretion of VLDL in the liver. Among the patatin homology domain family, PNPLA4 and PNPLA5 have been observed to exhibit TAG hydrolyse, DAG transacylase and retinylester hydrolyse activity in vitro, which needs to be confirmed in vivo. Noteworthy, the member with the highest ATGL homology is PNPLA3 or adiponutrin. Lipid droplet proteins: perilipin. Lipid droplets in most tissues are coated by two or more members of the perilipin family, which are now numbered according to the order of discovery. Expression of perilipin-1 is mainly restricted to white and brown adipocytes and, to a lesser extent, steroidogenic cells of adrenal cortex, testes and ovaries. Perilipin-2 (formerly adipophilin or ADRP) and perilipin-3 (formerly TIP47) are ubiquitously expressed and, therefore, lipid droplet components of most tissues. While perilipin-4 (formerly S3-12) is primarily expressed in white adipocytes, perilipin-5 (formerly OXPAT, MLD, or LSD5) is expressed in brown adipocytes as well as myocytes of skeletal muscle and heart, all of which rely on lipolysis to provide fatty acids to mitochondria for β-oxidation to drive either ATP production or heat generation. Thus, the perilipin composition of lipid droplets within a specific tissue constitutes an important component of lipolysis regulation.

Perilipin is the best-known member of the PAT family, with perilipin-1 being the predominant isoform found in mature adipocytes, the most abundant protein on the lipid droplet surface and the major substrate for cAMP-dependent PKA in lipolytically stimulated adipocytes. Perilipin limits the access of cytosolic lipases to lipid droplets, thereby facilitating TAG storage under basal conditions (Fig. 3(a)). When energy is needed, perilipin is phosphorylated by PKA, facilitating maximal lipolysis by ATGL and HSL (Fig. 3(b)). Thus, perilipin expression and its phosphorylation state are key in lipolysis control, with phosphorylation of Ser492 producing a lipid droplet remodelling, widely increasing the surface area for lipase binding, while Ser517 is essential for ATGL-dependent lipolysis in stimulated conditions. Perilipin-1 is also phosphorylated by the cyclic GMP-dependent PKG.

Perilipin ablation confers resistance to genetic or diet-induced obesity, producing a lean phenotype with smaller adipocytes, increased basal lipolysis and attenuated stimulated lipolysis. Recently, perilipin-1 has been shown to move between the fat droplet and the endoplasmic reticulum, which is physiologically reasonable given that...
lipid droplets are largely derived from the endoplasmic reticulum. In this regard, perilipin-mediated lipid droplet formation in adipocytes was demonstrated to promote sterol regulatory element-binding protein-1 (SREBP-1) processing and TAG accumulation, suggesting an interplay between lipid droplet formation and SREBP-1 activation via a positive feedback loop. Therefore, the lysosomal protein degradation machinery of perilipin may constitute a target mechanism for enhancing adipocyte lipolysis. Interestingly, a genome-wide RNA interference (RNAi) screen in Drosophila S2 cells highlighted the relevance of elements of the vesicle-transport systems in lipolysis regulation through the identification of the vesicle-mediated coat protein complex I (COPI) as an evolutionarily-conserved regulator of PAT protein composition at the lipid droplet surface. In addition to regulating PAT protein composition, COPI promotes the association of ATGL with the lipid droplet surface to mediate lipolysis. These genes are conserved in mammalian cells, thus suggesting that a similar complex might be operative in adipocytes. Although COPI-mediated transport reportedly participates in delivery of ATGL to the lipid droplet surface, depletion of β-COP (a subunit of the COPI coat complex) does not affect association of ATGL with lipid droplets or ATGL-mediated lipolysis, pointing to the possibility of alternative transport mechanisms implicated in the regulation of lipid homeostasis.

**Lipid droplet proteins: coactivator comparative gene identification-58 (CGI-58) or α/β-hydrolase domain-containing protein 5 (ABHD5).** CGI-58 lacks lipase activity in itself but potently and selectively stimulates lipolysis by activating ATGL. As mentioned above, in basal unstimulated conditions CGI-58 binds tightly to lipid droplets by interacting with perilipin-1 and is unable to activate ATGL. However, following β-adrenoceptor stimulation CGI-58 is quickly dispersed to the cytosol, favouring ATGL co-localisation and migration to small lipid droplets. Thus, under stimulated conditions, the intracellular cAMP elevation and PKA activation promote perilipin-1 phosphorylation, which is followed by the dissociation from perilipin of CGI-58, which subsequently interacts with ATGL and activates TAG hydrolysis (Fig. 3(b)). In addition to ATGL activation, a further physiological function for CGI-58 in phospholipid synthesis with lysophosphatidic acid acyltransferase activity has been observed.

**Lipid droplet proteins: Cide domain-containing proteins.** A further family of lipid droplet-associated proteins encompasses the cell death-inducing DFFA (DNA fragmentation factor-α)-like effectors (Cide), which includes three members (Cidea, Cideb and Cidec/Fsp27) with tissue-specific expression. In spite of Cidea and Cideb not being expressed in white adipose tissue, their deletion yielded rodents with lower body weight and improved insulin sensitivity as well as resistant to diet-induced obesity. In the Cidea knockout model the elevated energy expenditure was attributable to brown adipose tissue via enhanced AMPK activity leading to increased fatty acid oxidation. The Cideb mutants exhibited a decreased hepatic VLDL secretion and de novo fatty acid oxidation related to enhanced hepatic oxidative activity. Cidea is also involved in human adipocyte lipolysis, TAG deposition and fatty acid oxidation via cross-talk with TNF-α, which inhibits the transcription of the gene. Cidea co-localises with perilipin around lipid droplets in fat cells. An increased lipolysis is observed in Cidea-depleted human adipocytes. Contrarily, ectopic expression of Cidea in preadipocytes markedly enhances lipid droplet size, promoting lipid accumulation. Noteworthy, Cidea expression is elevated in human cancer cachexia, exhibiting a correlation with elevated NEFA concentrations and weight loss. In humans Cidec, also referred to as fat-specific protein 27, FSP27, is predominantly expressed in subcutaneous adipocytes, being down-regulated in response to a reduced energy intake. Small interfering RNA-mediated knockdown of Cidec translated into an increased basal release of NEFA, and decreased responsiveness to adrenergic lipolysis stimulation. The interaction between the diverse lipases is also starting to be unfolded. FSP27 and perilipin-1 interaction promotes the formation of large lipid droplets in human adipocytes. Recently, the unilocular to multilocular transformation that takes place during ‘browning’ of white adipose tissue has been related to Cide-triggered dynamic changes in lipid droplet-associated proteins.

**Lipid droplet proteins: other proteins (GPIHBP1 and Rab).** Glycosylphosphatidylidyinositol-anchored HDL-binding protein (GPIHBP1) is a 28-kDa glycosylphosphatidylinositol-anchored glycoprotein located on the luminal surface of endothelial cells in tissues where lipolysis takes place such as adipose tissue, skeletal muscle and heart. GPIHBP1 knockout mice exhibit chylomicronaemia, even on a low-fat diet, with highly elevated plasma TAG concentrations. GPIHBP1 is highly expressed in the same tissues that express high levels of LPL, namely, heart, adipose tissue, and skeletal muscle where it binds both LPL and chylomicrons, suggesting that GPIHBP1 functions as a platform for LPL-dependent lipolytic processing of TAG-rich lipoproteins, stabilising LPL without activating it.

Rab GTPases, which are key regulators of membrane trafficking, have emerged as particularly relevant molecules in the highly dynamic cellular interactions involved in lipid mobilisation. In this sense, proteomic analyses have consistently identified the small GTPase Rab18 as a component of the lipid droplet coat. Thus, Rab18 provides an excellent marker to follow the dynamics of lipid droplets in living cells as well as to gain insight into the complex regulatory mechanisms involved in lipid storage and release. In 3T3-L1 adipocytes, stimulation of lipolysis increases the association of Rab18 with lipid droplets,
suggesting that Rab18 recruitment is regulated by the metabolic state of individual lipid droplets. Furthermore, Rab1a and its effector protein are reportedly involved in the CD36 trafficking signalling pathway(259).

**Integral membrane proteins and transporters.** While the main signalling cascades and regulators of lipolysis have been identified, the cellular interactions involved in lipid mobilisation and release still remain to be completely disentangled. Except in adipocytes, lipid droplets are normally small, mobile and interact with other cellular compartments in cells. On the contrary, fat cells are composed mainly of very large, immotile lipid droplets. The striking morphological differences between lipid droplets in adipocytes and non-adipocytes suggest that key differences must exist in the way in which lipid droplets in different cell types interact with other organelles to facilitate lipid transfer. A plethora of molecules involved in these interactions are now emerging, with integral membrane proteins and fatty acid transporters standing out as pivotal elements operating at the dynamic plasma membrane–lipid droplet interface.

**Integral membrane proteins and transporters: aquaporin-7.** Aquaporins (AQP) are integral membrane proteins that function mainly as water channels. AQP7 belongs to the subfamily of aquaglyceroporins, which are permeable to both glycerol and water, being expressed in adipocytes(339–341). Mouse and human AQP7 exhibit six prospective sites for PKA phosphorylation, suggesting a putative cAMP/PKA-dependent regulation. Aqp7-knockout mice show defective glycerol exit from fat cells, adipocyte hypertrophy due to TAG accumulation and moderate adult-onset obesity.(342,343) Short-term regulation and translocation of AQP7 to the plasma membrane is stimulated by catecholamines, while insulin exerts a long-term negative control. More recently, in addition to AQP7, the presence and functionality of other members of the aquaglyceroporin subfamily, AQP3 and AQP9, have been identified in adipose tissue and shown to be regulated by insulin and leptin via the PI3K/Akt/mTOR signalling cascade(344).

**Integral membrane proteins and transporters: caveolin-1.** Caveolae account for over 25 % of the adipocyte's membrane, being specialised plasma membrane microdomain invaginations involved in important cellular transport processes such as endo- and transcytosis as well as signal transduction(345). Three classes of caveolae formed by caveolin-1, the scaffolding hairpin-like protein facing the cytosol, have been identified, with high-density caveolae taking up exogenous fatty acids and converting them to TAG. These TAG-metabolising caveolae serve as a platform for FABP4, fatty acid transport protein (FATP) 1 and 4 (FATP1 and FATP4), long-chain acyl-CoA synthetase 1 (ACSL1) and CD36 (also known as fatty acid translocase). Noteworthy, these caveolae contain FATP1 and FATP4 together with the enzymes needed for TAG synthesis(346–348). Furthermore, HSL and perilipin have been shown to be associated to these caveolae(349), demonstrating that TAG can be hydrolysed in them (Fig. 4). Caveolin-1 exerts an indirect structural role in caveolae formation, controlling surface availability or stability of CD36, a fatty acid transporter key to long-chain fatty acid uptake(350). In response to NEFA, caveolin-1 reportedly translocates from the plasma membrane to lipid droplets. Caveolin-1 knockout mice lack caveolae in adipocyte plasma membranes, exhibiting increased circulating NEFA and TAG, reduced adipocyte lipid droplet size and resistance to diet-induced obesity.(351) Experiments with caveolin-1-null mouse embryonic fibroblasts indicate that caveolin-1 deficiency is followed by a total loss of caveolae, absence of CD36 plasma membrane expression and a reduction in fatty acid uptake, which is reverted by re-expression of caveolin-1(352). Interestingly, caveolin-1 has been shown to exert inhibitory interactions with various proteins such as PKA, endothelial NOS and insulin receptors, with knockout mice exhibiting an attenuated lipolytic activity and decreased perilipin phosphorylation(349). Caveolin-1 potently inhibits CAMP-dependent signalling in vitro, with a direct interaction between caveolin-1 and the catalytic subunit of PKA having been demonstrated both in vitro and in vivo.

**Integral membrane proteins and transporters: fatty acid translocase (CD36).** As mentioned above, CD36 localises to caveolae as well as to intracellular vesicles. CD36 is a glycoprotein belonging to the family of class B scavenger receptors predicted to have two transmembrane domains at the N- and C-terminal, a large extracellular domain loop and two short intracellular cytoplasmic tails(259). CD36 is expressed in organs with high fatty acid metabolism rates, such as adipose tissue, operating as a NEFA scavenger. Insulin activation of the forkhead transcription factor and AMPK stimulation trigger CD36 translocation from intracellular stores to the plasma membrane, thereby enhancing NEFA uptake. CD36 deficiency is associated with increased basal lipolysis and responsiveness to the anti-lipolytic effect of insulin, with Cd36-null mice exhibiting an impaired fatty acid uptake in metabolic tissues (including adipocytes) and increased plasma NEFA and TAG concentrations(353,354). Knockdown of CD36 by RNAi in 3T3-L1 adipocytes resulted in a profound reduction of both basal and insulin-stimulated NEFA uptake. Conversely, overexpression of CD36 led to mice with decreased adiposity and low circulating levels of NEFA, TAG and cholesterol, suggesting that a strict control of these molecules for an effective lipolysis is required.

**Integral membrane proteins and transporters: adipocyte fatty acid binding protein.** FABP4, also known as ALBP and aP2, is a cytosolic lipid-binding protein highly expressed in adipocytes involved in fatty acid and retinoid acid intracellular trafficking(259). It acts as a molecular chaperone, facilitating NEFA uptake and lipolysis, interacting with HSL and shuttling fatty acids out of adipocytes (Fig. 4). Upon PKA activation the HSL–FABP4 complex translocates to lipid droplets. Consistently with this, in Fabp4-knockout mice basal and stimulated lipolysis are...
attenuated\(^{(291,555–557)}\). Interestingly, \(Fabp4\)-null mice have been shown to compensate \(FABP4\) deletion by increasing the expression of other \(FABP\), thereby highlighting that lipolysis seems to be linked to total \(FABP\) content rather than to a specific \(FABP\) type\(^{(4)}\).

**Integral membrane proteins and transporters: fatty acid transport protein 1**. The underlying mechanism for fatty acid uptake by \(FATP1\), an integral membrane protein of about 71 kDa with a hydrophobic domain at the N-terminal that may be membrane-anchored and other membrane-associated domains peripherally associated with the inner leaflet of the membrane, is still unknown. In response to insulin, \(FATP1\) may translocate to structurally disordered non-lipid raft regions of the plasma membrane. Subsequently, \(FATP1\) may extract fatty acid from the inner membrane leaflet and esterify it to \(CoA\), thereby preventing its efflux and driving a NEFA concentration gradient across the membrane\(^{(358,359)}\). Most of the incoming fatty acids are converted into acyl-CoA and preferentially shunted into TAG synthesis (Fig. 4). Noteworthy, the conversion of incoming long-chain fatty acids to TAG takes place on or around the plasma membrane in rat adipocytes, plausibly linking in a mechanistic way fatty acid influx to TAG synthesis\(^{(259,360)}\). Knockdown and knockout experiments revealed an absolute requirement for \(FATP1\) in insulin-stimulated fatty acid uptake, whereas \(FATP1\) overexpression led to a fatty acid uptake increase.

**Integral membrane proteins and transporters: fatty acid transport protein 4**. \(FATP4\) presents a 60 % identity to \(FATP1\) and is expressed in adipose tissue, skin, heart, skeletal muscle, liver, as well as in the small intestine, where it was observed to work in intestinal lipid absorption\(^{(259,361)}\). \(FATP4\) knockdown in 3T3-L1 adipocytes by RNAi did not affect basal and insulin-stimulated fatty acid uptake. \(FATP4\) knockouts exhibit perinatal lethality due to restrictive dermopathy, suggesting a key role in the formation of the epidermal barrier rather than in fatty acid uptake and intestinal lipid absorption.

**Integral membrane proteins and transporters: acyl-CoA synthetase long-chain 1**. \(ACSL1\), a 78-kDa membrane protein expressed in adipocytes and localised to various subcellular sites including the plasma membrane, lipid droplets, and GLUT4-containing vesicles, co-localises with \(FATP1\)\(^{(259)}\). \(ACSL1\) knockdown in 3T3-L1 adipocytes by RNAi did not affect basal and insulin-stimulated fatty acid uptake. \(ACSL1\) knockouts exhibit perinatal lethality due to restrictive dermopathy, suggesting a key role in the formation of the epidermal barrier rather than in fatty acid uptake and intestinal lipid absorption.

---

\(\text{Fig. 4. Schematic diagram of a caveola present in the adipocyte's membrane and its participation in lipolysis.} \) ACSL1, acyl coenzyme A synthetase 1; cAMP, cyclic AMP; CD36, fatty acid translocase; FA, fatty acid; \(FABP\), fatty acid binding protein; \(FATP\), fatty acid transport protein; HSL, hormone-sensitive lipase; LD, lipid droplet; NOS, NO synthase; PKA, protein kinase A; \(PP\), pyrophosphate. (A colour version of this figure can be found online at http://www.journals.cambridge.org/nrr)\)
by RNAi in 3T3-L1 adipocytes points to a role in fatty acid efflux but not influx.

**Depot-specific differences**

The main anatomical fat depots in humans include intra-abdominal (greater and lesser omental and mesenteric depots, also known as visceral fat), lower-body (gluteal, subcutaneous leg and intramuscular fat) and upper-body subcutaneous fat\(^3\). Subcutaneous adipose tissue constitutes the largest site for fat storage (about 80 % of total body fat), while under normal circumstances visceral adipose tissue accounts for a small fraction of body fat (about 20 % in men, and 5–8 % in women)\(^3\). Regional differences, including preadipocyte replication and differentiation, adipocyte size, blood supply, gene expression, basal metabolic activities and hormonal responsiveness, contribute to regional fat distribution\(^3\). Increased NEFA availability, resulting from increased effective adipose tissue lipolysis, plausibly underlies some of the visceral obesity-associated metabolic alterations\(^3\). Owing to its anatomical distribution, NEFA released from visceral adipose tissue are drained directly to the liver through the portal vein, whereas venous drainage of NEFA from subcutaneous adipose tissue is through systemic veins\(^3\). The venous drainage of fat via the portal system directly provides NEFA as substrates for hepatic lipoprotein metabolism or glucone production. Excess NEFA favours the onset of dyslipidaemia, hyperinsulinaemia and insulin resistance by reducing hepatic degradation of apoB and insulin as well as by increasing VLDL production\(^3\).

Table 1 summarises regional variations in adipocyte lipolysis leading to increased NEFA release from visceral as compared with subcutaneous fat during hormone stimulation. Visceral adipocytes show the highest lipolytic responsiveness to catecholamines due to an increased function of the lipolytic \(\beta_1\), \(\beta_2\) and \(\beta_3\)-adrenoceptors\(^3\). On the other hand, as mentioned above, several mechanisms have been linked to the weak lipolytic response to catecholamines in subcutaneous adipocytes, such as enhanced anti-lipolytic \(\alpha_2\)-adrenoceptor activity, decreased lipolytic \(\beta_2\)-adrenoceptor responsiveness as well as reduced expression or function of HSL, FABP4 or perilipin\(^3\). The anti-lipolytic effect of insulin is more prominent in subcutaneous adipocytes compared with visceral fat cells\(^3\). Regional differences involve insulin receptor affinity, which is partly caused by variations in the insulin dissociation rate, but also by reduced insulin receptor phosphorylation and signal transduction via the IRS-1/PI3K pathway\(^3\). Testosterone has been reported to show both stimulatory \(374\) (i.e. up-regulation

![Table 1. Depot-specific differences of diverse factors regulating adipocyte lipolysis](https://www.cambridge.org/core/terms). https://doi.org/10.1017/S095442241400002X

<table>
<thead>
<tr>
<th>Regulatory factor</th>
<th>Activity</th>
<th>Main fat depot target</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Catecholamines</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(\beta_1)-Adrenerceptor</td>
<td>Lipolytic</td>
<td>Visceral adipose tissue</td>
<td>370</td>
</tr>
<tr>
<td>(\beta_2)-Adrenerceptor</td>
<td>Lipolytic</td>
<td>Visceral adipose tissue</td>
<td>370</td>
</tr>
<tr>
<td>(\beta_3)-Adrenerceptor</td>
<td>Lipolytic</td>
<td>Visceral adipose tissue</td>
<td>370</td>
</tr>
<tr>
<td>(\alpha_2)-Adrenerceptor</td>
<td>Anti-lipolytic</td>
<td>Subcutaneous fat</td>
<td>370</td>
</tr>
<tr>
<td><strong>Insulin</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Growth hormone</strong></td>
<td>Lipolytic</td>
<td>Unknown</td>
<td>431</td>
</tr>
<tr>
<td><strong>Ghrelin/obestatin</strong></td>
<td>Lipolytic</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td><strong>Growth hormone secretagogue receptor</strong></td>
<td>Anti-lipolytic</td>
<td>Visceral and subcutaneous fat</td>
<td>432, 433</td>
</tr>
<tr>
<td><strong>Testosterone</strong></td>
<td>Anti-lipolytic</td>
<td>Subcutaneous fat</td>
<td>75</td>
</tr>
<tr>
<td><strong>Androgen receptors</strong></td>
<td>Anti-lipolytic</td>
<td>Subcutaneous fat</td>
<td></td>
</tr>
<tr>
<td>Oestrogens</td>
<td>Anti-lipolytic</td>
<td>Subcutaneous fat</td>
<td>375</td>
</tr>
<tr>
<td>Oestrogen receptor-(\alpha)</td>
<td>Anti-lipolytic</td>
<td>Subcutaneous fat</td>
<td></td>
</tr>
<tr>
<td><strong>Endothelin</strong></td>
<td>Anti-lipolytic</td>
<td>Subcutaneous fat</td>
<td>217</td>
</tr>
<tr>
<td><strong>Endothelin receptor A</strong></td>
<td>Lipolytic</td>
<td>Unknown</td>
<td>216</td>
</tr>
<tr>
<td><strong>Endothelin receptor B</strong></td>
<td>Lipolytic</td>
<td>Visceral adipose tissue</td>
<td></td>
</tr>
<tr>
<td><strong>TNF-(\alpha)</strong></td>
<td>Lipolytic</td>
<td>Unknown</td>
<td>434</td>
</tr>
<tr>
<td><strong>TNF receptor 1</strong></td>
<td>Lipolytic</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td><strong>IL-6</strong></td>
<td>Lipolytic</td>
<td>Visceral adipose tissue</td>
<td>131, 435</td>
</tr>
<tr>
<td><strong>IL-6 receptor and glycoprotein 130</strong></td>
<td>Lipolytic</td>
<td>Visceral adipose tissue</td>
<td></td>
</tr>
<tr>
<td><strong>Lipopolysaccharide</strong></td>
<td>Lipolytic</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td><strong>Toll-like receptor 4</strong></td>
<td>Lipolytic</td>
<td>Unknown</td>
<td>436</td>
</tr>
<tr>
<td><strong>Leptin</strong></td>
<td>Lipolytic</td>
<td>Subcutaneous fat</td>
<td>376</td>
</tr>
<tr>
<td><strong>Leptin receptor: OB-R</strong></td>
<td>Lipolytic</td>
<td>Subcutaneous fat</td>
<td></td>
</tr>
<tr>
<td><strong>Adiponectin</strong></td>
<td>Anti-lipolytic</td>
<td>Subcutaneous fat</td>
<td>164</td>
</tr>
<tr>
<td><strong>Full-length adiponectin</strong></td>
<td>Anti-lipolytic</td>
<td>Subcutaneous fat</td>
<td>164</td>
</tr>
<tr>
<td><strong>Globular adiponectin</strong></td>
<td>Anti-lipolytic</td>
<td>Visceral and subcutaneous fat</td>
<td>164</td>
</tr>
<tr>
<td><strong>Trimeric adiponectin</strong></td>
<td>Anti-lipolytic</td>
<td>Visceral and subcutaneous fat</td>
<td>164</td>
</tr>
<tr>
<td><strong>Natriuretic peptides</strong></td>
<td>Anti-lipolytic</td>
<td>Subcutaneous fat</td>
<td></td>
</tr>
<tr>
<td><strong>Atrial natriuretic peptide</strong></td>
<td>Lipolytic</td>
<td>Visceral and subcutaneous fat</td>
<td>378</td>
</tr>
<tr>
<td><strong>Brain natriuretic peptide</strong></td>
<td>Lipolytic</td>
<td>Unknown</td>
<td>377</td>
</tr>
<tr>
<td><strong>C-type natriuretic peptide</strong></td>
<td>Lipolytic</td>
<td>Unknown</td>
<td>377</td>
</tr>
</tbody>
</table>
of β2-adrenoreceptors in visceral fat cells) and inhibition(75) (i.e. down-regulation of β2-adrenoreceptors and HSL in subcutaneous adipocytes) effects on catecholamine-induced lipolytic activity. Oestrone attenuates the lipolytic response through up-regulation of a number of anti-lipolytic α2-adrenergic receptors(375).

Leptin and adiponectin, the most abundant adipocyte-secreted factors, show opposite actions on lipolysis regulation(12). Leptin produces a significantly greater stimulation of lipolysis in subcutaneous fat cells compared with omental adipocytes(576). Adiponectin has recently emerged as an anti-lipolytic factor on binding adiponectin receptor type 1 and 2 (AdipoR1 and AdipoR2). Full-length adiponectin exerts an anti-lipolytic action in subcutaneous adipose tissue in non-obese subjects, while exhibiting no effect on visceral fat(163,164). Atrial (ANP), brain (BNP) and C-type (CNP) natriuretic peptides also induce lipolysis in human abdominal adipocytes, with the potency order of the lipolytic effect being ANP > BNP > CNP(577). ANP-induced lipolysis is not subjected to primary regional regulation in differentiated human subcutaneous and visceral fat cells(578). Fat-depot differences in the lipolytic effect of BNP and CNP remain to be established.

In addition to the physiological depot-specific differences in the neuroendocrine control of adipose tissue, it is important to consider the role of body fat distribution in the development of cardiometabolic alterations(365–366). Adipose tissue distribution varies with sex, age, genetic background, nervous and endocrine factors, nutritional and pharmacological influences as well as disease state, which impinge on preadipocyte replication and differentiation, developmental gene expression, vasculature, inflammation, adipokine secretion and apoptosis. The excess visceral fat observed in obesity is closely linked with metabolic and cardiovascular co-morbidities, whereas increased subcutaneous fat may even exert protective effects. However, how inter depot differences in the molecular, cellular, histological and pathophysiological properties translate into co-morbidity development needs to be fully unravelled(379–381).

Lipophagy: role of autophagy in lipid metabolism

Autophagy is a self-digestive process that entails the formation of double-membrane vesicles, termed autophagosomes, that sequester and target cytoplasmic cargo for lysosomal degradation(382–384). In addition to quality control, autophagy also regulates lipid metabolism by degrading lipid droplets via lipophagy (Fig. 5). Small lipid droplets can be completely taken up by an autophagosome, whereas increased subcutaneous fat may even exert protective effects. However, how inter depot differences in the molecular, cellular, histological and pathophysiological properties translate into co-morbidity development needs to be fully unravelled(379–381).

Adipocyte lipolysis control 79

regulated proteins to the VPS34 complex (class III PI3K), which is essential for the activity of the phagophore(585). During the vesicle elongation process, ATG7 induces the conjugation of ATG12 to ATG5 as well as the conjugation of cytosolic light chain 3 (LC3)-I to phosphatidylethanolamine to generate LC3-II, one of the best-characterised components of autophagosomes. Once formed, autophagosomes engulf lipid droplets and eventually fuse with a hydrolyase-containing lysosome, the lipases of which degrade lipids(582). This process generates fatty acids that are released into the cytoplasm and can be oxidised in the mitochondria to generate ATP to maintain energy homeostasis. Under basal fed conditions, nutrients (particularly amino acids) or insulin and growth factors trigger the activity of class I PI3K that, in turn, activates mTOR, the best-characterised negative regulator of autophagy, and blocks autophagosome formation(586,587) (Fig. 5). As a result, lipid breakdown by autophagy is minimal in the fed state.

Autophagy also participates in adipocyte differentiation regulation(588). Transgenic animals lacking the autophagy-related proteins ATG5 and ATG7 show a reduction in adipose mass, supporting that autophagy is essential for normal adipogenesis(389,390). Analogously, Atg5 and Atg7 knockdown in 3T3-L1 adipocytes decrease intracellular lipid content and gene expression levels of the key adipogenic transcription factors, CCAAT/enhancer-binding protein α and β (C/EBPα and β) and PPAR-γ(389). White adipocytes of Atg7-deficient mice acquire some characteristics of brown adipocytes, such as higher mitochondrial content, multilocular lipid droplets and increased levels of the brown adipogenic factors PPAR-γ, C/EBPα and UCP-1, triggering adipose tissue fatty acid β-oxidation(590). Interestingly, loss of Atg7 disrupts brown fat differentiation and promotes the ‘beige’ (brown adipocyte-like) cell development in inguinal adipose tissue, thereby contributing to increased energy expenditure(591,592).

Human adipose tissue contains autophagosomes and obesity is associated with an altered expression of the autophagy-related proteins LC3-I, LC3-II, beclin-1, ATG5 and ATG7(200,393,593). Markers of autophagy are correlated with whole-body adiposity, visceral fat distribution and adipocyte hypertrophy. However, the altered expression of autophagy in human obesity appears to be related to the degree of insulin resistance, rather than to excess adiposity(200). In this sense, insulin constitutes a major inhibitor of autophagy, with insulin resistance being a potential activator of this process, since patients with type 2 diabetes show elevated formation of autophagosomes in subcutaneous adipose tissue(95).

Adipocyte autophagy is also regulated by TNF-α and ghrelin, showing opposite effects on the regulation of fat storage in human adipocytes(200). TNF-α plays an important role in the pathophysiology of deranged lipid metabolism through both the suppression of LPL activity and enhancement of lipolysis in human fat cells(595). In addition, TNF-α also triggers autophagy by increasing the transcript levels of Becn1.
(beclin 1), required for the formation of the autophagosome initiation complex, as well as those of ATG5, and ATG7, the autophagy proteins involved in the conjugation cascades for autophagosome elongation in human adipocytes\(^{200}\). On the other hand, ghrelin is a gut-derived hormone that promotes adiposity through orexigenic and adipogenic actions\(^{199,397}\). Ghrelin isoforms (acylated and desacyl ghrelin) stimulate the expression of several fat storage-related proteins such as acetyl-CoA carboxylase, fatty acid synthase, LPL or perilipin through central mechanisms\(^{397}\) and directly acting on human adipocytes\(^{199}\), thereby stimulating intracellular lipid accumulation. Besides its lipogenic action, acylated ghrelin reduces basal ATG5 and ATG7, while desacyl ghrelin inhibits TNF-α-induced expression of ATG5, ATG7 and BECN1. Taken together, ghrelin constitutes a negative regulator of basal and TNF-α-induced autophagy in human visceral adipocytes\(^{200}\).

Novel fascinating findings in the field of adipocyte apoptosis have been recently reported\(^{398,399}\). White adipose tissue inflammation, a characteristic feature of obesity, results from the death of hypertrophic adipocytes that are subsequently cleared by macrophages, giving rise to crown-like structures (CLS). It has been recently shown that infiltrating macrophages actively take up remnant lipids of dead adipocytes\(^{398}\). Upon induction of adipocyte apoptosis, inflammatory cells infiltrate adipose tissue initially consisting of neutrophils followed by macrophages that are involved in CLS formation. Moreover, subcutaneous and visceral hypertrophic adipocytes obtained from obese mice exhibit ultrastructural abnormalities (cholesterol crystals and Ca accumulation), being more common in the hyperglycaemic \(db/db\) v. normoglycaemic \(ob/ob\) mice and in the visceral v. subcutaneous depots. Data indicate that white adipocyte overexpansion induces a stress state that ultimately leads to death with NOD-like receptor family, pyrin domain containing 3 (NLRP3)-dependent caspase-1 activation in hypertrophic adipocytes probably inducing obese adipocyte death by pyroptosis, a proinflammatory programmed cell death\(^{399}\).

**Lipolysis in human obesity**

Obesity is characterised by a marked secretion of pro-inflammatory adipokines, including TNF-α, and a profound decrease in adiponectin synthesis\(^{234}\). The increased TNF-α production in adipose tissue triggers MAP kinase
activity in adipocytes, thus altering the action of perilipin and leading to an enhanced basal lipolytic rate\(^{(2,403)}\). Otherwise, adiponectin inhibits basal and catecholamine-induced lipolysis in non-obese subjects, but this effect is lost in obesity\(^{(161)}\). The isoform-specific ability to prevent lipolysis is modified in obesity. While full-length adiponectin exerts an anti-lipolytic action in subcutaneous fat, without effect on visceral fat, in non-obese individuals, the lower adiponectin isoforms (globular and trimeric) become important actors in obesity, showing anti-lipolytic activity in obese subcutaneous and visceral adipose tissue, respectively\(^{(164)}\).

Circulating NEFA and glycerol concentrations are elevated in obesity, suggesting an increase in overall lipolysis during fasting\(^{(344)}\). Several impairments in the control of lipolysis have been reported in obese individuals, including an altered responsiveness to catecholamines\(^{(2,4,53)}\). Obese subjects show a lower lipolytic effect of catecholamines in subcutaneous adipose tissue through decreased action of lipolytic \(\beta_2\)-adrenergic receptors and increased activity of the anti-lipolytic \(\alpha_2\)-adrenergic adrenoceptors\(^{(370,401)}\). In this regard, a blunted lipolytic response has been shown in abdominal subcutaneous adipose tissue of obese individuals during intravenous infusion of the non-selective \(\beta\)-agonist isoprenaline\(^{(402)}\). On the other hand, catecholamine-induced lipolysis is markedly increased in visceral fat due to increased activity of \(\beta_3\)-adrenergic receptors and decreased activity of \(\alpha_2\)-adrenergic adrenoceptors\(^{(370,401)}\). In subjects with upper-body obesity these regional variations in the action of catecholamines on lipolysis are further enhanced\(^{(368,570)}\). These abnormalities in catecholamine function promote the release of NEFA from the visceral adipocytes through the portal system and might cause several of the metabolic complications of upper-body obesity. In addition, several polymorphisms in genes encoding \(\beta_1\) (\(ADRB1\), \(ADRB2\)) and \(\beta_2\) (\(ADRB3\)) adrenergic receptors have been associated with altered catecholamine-induced adipocyte lipolysis and with obesity\(^{(403,404)}\). The polymorphisms in the \(ADRB2\) gene are highly frequent in obesity and associated with altered \(\beta_2\)-adrenergic function (Arg16Gly and Gln27Glu) and catecholamine-induced lipolysis in subcutaneous fat cells (Arg16Gly and Thr164Ile)\(^{(42,405,406)}\). However, the \(ADRB1\) (Ser49Gly and Arg389Gly)\(^{(404,407,408)}\) and \(ADRB3\) (Trp64Arg)\(^{(409–411)}\) polymorphisms do not appear to be major determinants of \(\beta_1\)- and \(\beta_3\)-adrenergic function for lipolysis or the pathophysiology of obesity.

It is not clear whether the anti-lipolytic effect of insulin is affected in obesity, since the altered catecholamine concentrations found in the obese state counteract the effect of insulin\(^{(2)}\). Consequently, normal, decreased and increased anti-lipolytic effects of insulin have been reported in obese patients\(^{(41)}\). Insulin sensitivity of adipose tissue lipolysis is normal or slightly impaired in the adipose tissue of obese individuals\(^{(3,412)}\). Modifications of other anti-lipolytic factors may also be altered in obesity.

The pathological enlargement of fat cells in obesity compromises angiogenesis and increases the formation of hypoxic areas that promote the apoptosis of adipocytes and induce the fibrotic and inflammatory programme\(^{(387)}\). Apoptotic adipocytes are surrounded by M1-stage macrophages that form CLS in the adipose tissue. This process is accompanied by a chronic inflammation due to the secretion by adipose tissue-embedded immune cells and the dysfunctional adipocytes of proinflammatory cytokines and acute-phase reactants, such as TNF-\(\alpha\), C-reactive protein, IL-6, IL-8, leptin, serum amyloid A (SAA) and monocyte chemotactic protein (MCP)-1\(^{(2,532,534)}\). As detailed in the Cytokines and other ‘newcomers’ section, the increase in proinflammatory adipokines, such as TNF-\(\alpha\) or leptin, might be responsible for the high basal rate of lipolysis in obese patients.

Obesity is associated with a decreased expression and activity of HSL, but not ATGL, in visceral and subcutaneous adipocytes of obese individuals independently of age and sex, which may play an important role in the defective lipid mobilisation observed in obesity\(^{(413–415)}\). Furthermore, a decreased access of lipases to TAG due to alterations in lipid droplet-associated proteins cannot be ruled out\(^{(416–419)}\). In humans CGI-58 mutations have been identified in patients with Chanarin–Dorfman syndrome, a disorder characterised by the accumulation of abnormally large amounts of lipid droplets in several organs\(^{(420,421)}\). In these cases CGI-58 cannot be recruited to lipid droplets and fails to interact with perilipin, which may affect basal and PKA-stimulated lipolysis. Interestingly, CGI-58 gene silencing importantly reduces basal lipolysis by approximately 50% but also completely abrogates PKA-stimulated lipolysis in a human white adipocyte model\(^{(255,422)}\). The exact and complex dynamics involving CGI-58, the diverse perilipins and ATGL in basal as well as PKA-stimulated lipolysis has yet to be completely unravelled.

Finally, changes in the molecules involved in lipolysis-derived metabolites, fatty acids and glycerol also contribute to lipolytic derangements in obesity. Several proteins like FABP, CD36 or FATP facilitate fatty acid transport across the membrane in adipocytes\(^{(423)}\). The transport of the other lipolysis-derived metabolite, glycerol, from adipocytes in response to the lipolytic stimuli is facilitated by AQP3 and AQP7 via their translocation from the cytosolic fraction (AQP3) or lipid droplets (AQP7) to the plasma membrane\(^{(341,544,424,425)}\). AQP7 expression is decreased in subcutaneous adipose tissue of obese subjects, resulting in an increase in intracellular glycerol accumulation, which is converted to glycerol-3-phosphate by the glycerol kinase enzyme and re-esterified into TAG, thereby promoting adipocyte hypertrophy\(^{(344,426)}\). On the other hand, the increased AQP3 and AQP7 expression in visceral fat in obese subjects suggests an overall increase in the lipolytic activity in this fat depot in obesity\(^{(344,426,427)}\).
Concluding remarks and future perspectives

While adipose tissue elicited scarce interest for many decades\(^4\), the identification in 1994 of leptin as an adipose-derived hormone\(^5\) started a new era in adipobiology that recognises adipocytes as important dynamic endocrine cells. Essential lipolytic enzymes and a plethora of regulatory proteins and mechanisms have fundamentally changed our view of lipolysis and its impact, not only on adipose tissue but also more broadly on cellular metabolism\(^6\). Although the importance of lipolysis has been recognised for decades, many of the key proteins involved have been uncovered only recently. In this line, to further decipher the participation of lipolytic products and intermediates in many non-adipose tissues will be especially relevant to unravel previously underappreciated aspects of lipolysis and their relation to disease development. The regulation of lipolysis by numerous, and to some extent still incompletely identified, factors embodies the ‘liposome’, a complex metabolic network involved in ultimately controlling lipid mobilisation and fat storage. Information derived from the reactome linking the genome and metabolome via genome-sequence independent functional analysis of metabolic phenotypes and networks will be particularly fascinating. With the advent of systems biology a better integration of knowledge can be further expected to provide a more profound view of the true contribution of adipose tissue to health and disease.

Acknowledgements

The authors gratefully acknowledge the funding of the Spanish Instituto de Salud Carlos III, Fondo de Investigación Sanitaria – FEDER (project numbers CIBERobn CB06/03/1014, FIS PI10/01677 and PI12/00515) from the Ministerio de Economía y Competitividad, as well as the Plan de Investigación de la Universidad de Navarra (project PIUNA 2011-13). None of the funders had a role in the design, analysis or writing of this article.

All authors contributed fundamentally to the present paper. G. F. conducted the main review of the literature and drafted the manuscript. A. R. and L. M.-G. contributed significantly to the further drafting of the manuscript. All authors (G. F., L. M.-G., J. A. F.-F., S. F. and A. R.) made a critical review of the draft, provided input on data interpretation as well as commented on and approved the final manuscript.

The authors declare no conflicts of interest.

References

Nutrition Research Reviews


67. Samra JS, Clark ML, Humphreys SM, et al. (1999) Suppres-
sion of the nocturnal rise in growth hormone reduces subsequen


71. Gravholt CH, Møller N, Jensen MD, et al. (2001) Physiolo-
gical levels of glucagon do not influence lipolysis in abdominal adipose tissue as assessed by microdialysis. *J Clin Endocrinol Metab* **86**, 2085–2089.


89. Dicker A, Ryden M, Naslund E, et al. (2004) Effect of testoster-


92. Fan W, Yanase T, Nomura M, et al. (2005) Androgen recep-
tor null male mice develop late-onset obesity caused by decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion. *Diabetes* **54**, 1000–1008.


Adipocyte lipolysis control

87


Adipocyte lipolysis control


